Autoimmunity to glutamic acid decarboxylase in the neurodegenerative disorder Batten disease

The pathogenic mechanisms underlying Batten disease are unclear. Patients uniformly possess autoantibodies against glutamic acid decarboxylase (GAD) that are predominantly reactive with a region of GAD (amino acids 1 to 20) distinct from subjects with autoimmune type 1 diabetes or stiff-person syndrome. Batten patients did not possess autoantibodies against other type 1 diabetes-associated autoantigens and human leukocyte antigen genotypes revealed no specific associations with this disease.

[1]  Masumi Ito,et al.  An autoantibody inhibitory to glutamic acid decarboxylase in the neurodegenerative disorder Batten disease. , 2002, Human molecular genetics.

[2]  Jonathan D. Cooper,et al.  Targeted Disruption of the Cln3 Gene Provides a Mouse Model for Batten Disease , 1999, Neurobiology of Disease.

[3]  D. Neuberg,et al.  Heterophile antibodies segregate in families and are associated with protection from type 1 diabetes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[4]  B. Ollier.  Shock revelations about HLA–DR4 — a shortcut to rheumatoid arthritis? , 1996, Nature Medicine.

[5]  M. Atkinson,et al.  The clinical significance of an autoimmune response against glutamic acid decarboxylase , 1996, Nature Medicine.

[6]  J. Haines,et al.  Isolation of a novel gene underlying batten disease, CLN3 , 1995, Cell.

[7]  S. Mole.  Neuronal ceroid lipofuscinoses. , 1999, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.